5-三丁基锡-2-甲氧基吡啶 - CAS号 164014-93-1

物化性质

沸点：

397.5±52.0 °C(Predicted)

计算性质

辛醇/水分配系数(LogP)：

5.15
重原子数：

21
可旋转键数：

11
环数：

1.0
sp3杂化的碳原子比例：

0.72
拓扑面积：

22.1
氢给体数：

0
氢受体数：

2

安全信息

海关编码：

2933399090
WGK Germany：

3

SDS

SDS：e7ce3d62e698765f490fde30ab4c6a84

查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Methoxy-3-(Tributylstannyl)Pyridine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 398,16 g/mol
No components need to be disclosed according to the applicable regulations.

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
No special environmental precautions required.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

作为反应物：

描述：

5-三丁基锡-2-甲氧基吡啶在 copper(l) iodide 、四(三苯基膦)钯、四丁基溴化铵、 potassium hydroxide 作用下，以水为溶剂，反应 0.2h，生成 6'-methoxy-5-(thiophen-2-yl)-2,3'-bipyridine

参考文献：

名称：

微波辐照下在水中通过锡酰化/Stille 反应实现两种芳基卤的高效一锅交叉偶联

摘要：

一种简单高效的一锅法已被开发用于 Pd(PPh3)4 催化的两种不同芳基或杂芳基溴化物/碘化物的交叉偶联。该方法涉及组合使用微波辐射和水作为单一溶剂来实现顺序甲磺酰化和 Stille 交叉偶联反应，从而能够以良好到高产率快速获得各种联芳基化合物。此外，利用这种步骤经济的方案，2,5-二溴吡啶被反复二芳基化，并且啶酰菌胺中间体也以一锅法合成。

DOI：

10.1002/ejoc.201402404
作为产物：

描述：

2,5-二溴吡啶在甲醇、正丁基锂、 sodium 作用下，以四氢呋喃、正己烷、乙酸乙酯为溶剂，反应 50.0h，生成 5-三丁基锡-2-甲氧基吡啶

参考文献：

名称：

2-Aminopyridine compounds and use thereof as drugs

摘要：

本发明提供了一种具有优异腺苷受体（A1、A2a、A2b 受体）拮抗作用的 2-氨基吡啶化合物，其化学式如下：1（其中，R1代表氰基、羧基或可选择取代的氨基甲酰基；R2代表氢原子、羟基、可选择取代的C1-6烷氧基、可选择取代的C6-14芳香烃环基或可选择取代的 5-到 14-成员芳香杂环基；R3和 R4相同或不同，分别代表 C6-14芳香烃环基、 5-到 14-成员非芳香杂环基或可选择取代的 5-到 14-成员芳香杂环基，或其盐。

公开号：

US20040006082A1

点击查看最新优质反应信息

文献信息

SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS

申请人：BRISTOL-MYERS SQUIBB COMPANY

公开号：US20210188845A1

公开（公告）日：2021-06-24

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 6 or N; Y is CR 3 or N; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

揭示了Formula (I)的化合物：或其盐，其中：X为CR 6 或N；Y为CR 3 或N；R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 和m在此处定义。还揭示了使用这些化合物来抑制二酰甘油激酶α（DGKα）和二酰甘油激酶ζ（DGKζ）中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
Quinuclidine compounds and drugs containing the same as the active ingredient

申请人：Eisai Co., Ltd.

公开号：US06599917B1

公开（公告）日：2003-07-29

The present invention provides an excellent squalene synthesizing enzyme inhibitor. Specifically, it provides a compound (I) represented by the following formula, a salt thereof or a hydrate of them. In which R1 represents (1) hydrogen atom or (2) hydroxyl group; HAr represents an aromatic heterocycle which may be substituted with 1 to 3 groups; Ar represents an optionally substituted aromatic ring; W represents a chain represented by (1) —CH2—CH2— which may be substituted, (2) —CH═CH— which may be substituted, (3) —C≡C—, (4) —NH—CO—, (5) —CO—NH—, (6) —NH—CH2—, (7) —CH2—NH—, (8) —CH2—CO—, (9) —CO—CH2—, (10) —NH—S(O)l—, (11) —S(O)l—NH—, (12) —CH2—S(O)— or (13) —S(O)l—CH2— (l denotes 0, 1 or 2); and X represents a chain represented by (1) a single bond, (2) an optionally substituted C1-6 alkylene chain, (3) an optionally substituted C2-6 alkenylene chain, (4) an optionally substituted C2-6 alkynylene chain, (5) a formula —Q— (wherein Q represents oxygen atom, sulfur atom, CO or N(R2) (wherein R2 represents a C1-6 alkyl group or a C1-6 alkoxy group)), (6) —NH—CO—, (7) —CO—NH—, (8) —NH—CH2—, (9) —CH2—NH—, (10) —CH2—CO—, (11) —CO—CH2—, (12) —NH—S(O)m—, (13) —S(O)m—NH—, (14) —CH2—S(O)m—, (15) —S(O)m—CH2— (wherein m denotes 0, 1 or 2) or (16) —(CH2)n—O— (wherein n denotes an integer from 1 to 6).

本发明提供了一种优异的角鲨烯合成酶抑制剂。具体而言，它提供了一种由以下公式表示的化合物(I)、其盐或它们的 hydrate。在其中，R1代表（1）氢原子或（2）羟基； HAr代表一个可以由1到3个组替换的芳香杂环； Ar代表一个可选的取代的芳香环； W代表一个由（1）-CH2-CH2-，可以替换，（2） - ch & boxH; CH - 可被取代，（3） —C≡C—，（4） - NH - CO - ，（5） - CO - NH - ，（6） - NH - CH2 - ，（7） - CH2 - NH - ，（8） - CH2 - CO - ，（9） - CO - CH2 - ，（10） - NH - S(O)I - ，（11） - S(O)I - NH - ，（12） - CH2 - S(O) - 或（13） - S(O)I - CH2 - （I表示0、1或2）； X代表由（1）单个键，（2）可选地取代的C1-6烷基链，（3）可选地取代的C2-6烯基链，（4）可选地取代的C2-6炔基链，（5）式 - Q - （其中Q代表氧原子，硫原子，CO或N（R2）（其中R2代表C1-6烷基或C1-6烷氧基)），（6） - NH - CO - ，（7） - CO - NH - ，（8） - NH - CH2 - ，（9） - CH2 - NH - ，（10） - CH2 - CO - ，（11） - CO - CH2 - ，（12） - NH - S(O)m - ，（13） - S(O)m - NH - ，（14） - CH2 - S(O)m - ，（15） - S(O)m - CH2 - （其中m表示0、1或2）或（16） - (CH2) n - O - （其中n表示从1到6的整数)。
Fused pyridine derivatives

申请人：Eisai Co., Ltd.

公开号：US06340759B1

公开（公告）日：2002-01-22

The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2 represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

目前提供了一种由以下公式表示的缩合吡啶化合物（I）：（其中，R2代表环A代表苯环、吡啶环、噻吩环或呋喃环；B代表其药学上可接受的盐或其水合物，是一种具有血清素拮抗作用的临床上有用的药物，特别用于治疗、改善或预防痉挛性麻痹或改善肌张力过高的中枢肌肉松弛剂。
α-Iodocycloalkenones: Synthesis of (±)-epibatidine

作者：Nilantha S. Sirisoma、Carl R. Johnson

DOI：10.1016/s0040-4039(98)00187-7

日期：1998.4

A synthesis of the non-opiate analgesic alkaloid epibatidine was achieved in 13 steps and 13% overall yield starting from 1,3-cyclohexadiene using in a key step a modified Stille coupling reaction on an α-iodocyclohexenone.

非鸦片类止痛生物碱依巴替丁的合成从13位步骤开始，从1，3-环己二烯开始，以关键步骤使用在α-碘代环己烯酮上的改良Stille偶联反应，总收率达到13％。
Certain 1,3-disubstituted isoquinoline derivatives

申请人：Eisai Co., Ltd.

公开号：US20040204421A1

公开（公告）日：2004-10-14

Condensed pyridine compounds represented by formula (I): 1 wherein: R 1 and R 3 are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R 2 represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

公式（I）表示的浓缩吡啶化合物：1其中：R1和R3独立地表示氢、卤素、较低的烷基或较低的烷氧基；R2表示氨基取代基；环A是苯环、吡啶环、噻吩环或呋喃环；B表示含有环结构的取代基。此外，还包括其药学上可接受的盐和水合物。这些化合物是具有血清素拮抗作用的临床有用药物，特别是用于治疗、改善或预防痉挛性瘫痪。它们还可用作中枢肌肉松弛剂，以改善肌强直。

5-三丁基锡-2-甲氧基吡啶 | 164014-93-1

分子结构分类

物化性质

计算性质

安全信息

SDS

反应信息

文献信息

同类化合物

相关结构分类

热门分子